Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, Immunology, and Metabolic Disease Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for HDAC3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HDAC3 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Sf9 insect cell expressed for active conformation. |
View HDAC3 Products |
| Gene Delivery | HDAC3 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and target engagement assays. |
View HDAC3 Products |
| Benchmark Ab | Anti-HDAC3 Recombinant Antibody Recombinant positive control for western blot, IP, and IHC validation. |
View HDAC3 Products |
| Validator | HDAC3 siRNA Set For target knockdown verification and phenotypic validation. |
View HDAC3 Products |
| Related Target A | HDAC1 Class I HDAC homolog. Crucial for selectivity counter-screening. |
View HDAC1 Products |
| Related Target B | HDAC2 Class I HDAC homolog. High sequence identity with HDAC3; essential for off-target profiling. |
View HDAC2 Products |
| Related Target C | NCOR2 (SMRT) Essential co-repressor partner. HDAC3 requires NCOR2 interaction for enzymatic activation. |
View NCOR2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic Activity & Complex Assembly | Sf9 insect cell co-expressed HDAC3/NCOR2 complex available with verified purity and theoretical MW verification. |
| Isoform Selectivity (HDAC1/2/8 vs HDAC3) | Full panel of recombinant Class I HDAC proteins strictly verified by mass spectrometry to ensure zero cross-contamination. |
| Lack of Controls | Sequence-defined recombinant benchmark antibodies included for target validation. |
| False Positives in Small Molecule Screens | Validated HDAC3 siRNA pool included for target-specific knockdown rescue experiments. |
Live HDAC3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HDAC3 therapeutics is intensifying, with major players shifting focus from traditional pan-HDAC inhibitors to highly selective Class I inhibitors and PROTAC degraders. As first-generation pan-HDAC therapies face toxicity limitations in the clinic, the next wave of R&D is targeting HDAC3-specific complex disruption and selective degradation to spare HDAC1/2-associated hematological toxicities.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Selective Small Molecule | Incyte, Chipscreen Biosciences, Merck | T-cell Lymphoma, Solid Tumors | Selectivity Assay (Need highly purified HDAC1, HDAC2, and HDAC3 proteins) |
| PROTAC / Degrader | Arvinas, Kymera Therapeutics | Autoimmune Diseases, Hematological Malignancies | Target Engagement & Degradation Validation (Need Lentivirus for stable cell lines) |
| Dual-Target Inhibitors | Preclinical programs (HDAC3/PI3K, HDAC3/LSD1) | Resistant Solid Tumors | Synergy and Ortholog Profiling (Need multi-protein screening panels) |